$LTGO

$15.26 +$0.24 (1.6%) Close

$LTGO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 66.3M shares outstanding

Who owns LTGO?

By type of holder

Institutions 0.0% Insiders 28.9% Everyone else 71.1%

Concentration Top 10 holders own 45.9%

James B. Tananbaum 13.9% · Foresite Capital Fund V, L.P. 5.4%

Institutional ownership

0.0%

0.0 pts vs last qtr

Institutional holders

0 vs last qtr

Net shares bought

by institutions in Q2 2026

New / sold out

0 / 0

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

No 13F manager has reported this stock in the last 8 quarters.

Biggest buyers in Q2 2026

None.

Biggest sellers in Q2 2026

None.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Latigo Biotherapeutics, Inc. in the last 12 months.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for Latigo Biotherapeutics, Inc..

How patient are the owners?

No 13F manager reports holding LTGO.

Super Investors

Investment managers reporting LTGO on Form 13F

No 13F manager reports holding LTGO yet.

Institutional Funds

Mutual funds and ETFs reporting LTGO on Form N-PORT; together they hold 1.2% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
SB Select Biotechnology Portfolio Fidelity Select Portfolios	$10.6M	480.3K	0.72%	0.17%	August 31, 2026
SH Select Health Care Portfolio Fidelity Select Portfolios	$4.68M	212.5K	0.32%	0.07%	August 31, 2026

Select Biotechnology Portfolio

Fidelity Select Portfolios

Position value

$10.6M

% of company

0.72%

% of the fund

0.17%

As of

August 31, 2026

Select Health Care Portfolio

Fidelity Select Portfolios

Position value

$4.68M

% of company

0.32%

% of the fund

0.07%

As of

August 31, 2026

1 more funds behind a free account

See every fund holding Latigo Biotherapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
JB James B. Tananbaum 5%+ holder 13D · 14.5%	9.2M	13.85%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company13.850% Disclosed stake13D · 14.5% View the 13D/G filing →
FC Foresite Capital Fund V, L.P. 5%+ holder 13D · 5.6%	3.6M	5.37%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company5.370% Disclosed stake13D · 5.6% View the 13D/G filing →

James B. Tananbaum

5%+ holder13D · 14.5%

9.2M

% of company

13.85%

Change vs last qtr

—

Held since

—

Foresite Capital Fund V, L.P.

5%+ holder13D · 5.6%

3.6M

% of company

5.37%

Change vs last qtr

—

Held since

—

8 more holders behind a free account

See every insider and 5%+ holder of Latigo Biotherapeutics, Inc..

Comments